These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16773956)

  • 1. An Institutional Review Board dilemma: responsible for safety monitoring but not in control.
    DeMets DL; Fost N; Powers M
    Clin Trials; 2006; 3(2):142-8. PubMed ID: 16773956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using central IRBs for multicenter clinical trials in the United States.
    Flynn KE; Hahn CL; Kramer JM; Check DK; Dombeck CB; Bang S; Perlmutter J; Khin-Maung-Gyi FA; Weinfurt KP
    PLoS One; 2013; 8(1):e54999. PubMed ID: 23383026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application for academic multicenter studies at German ethical review boards].
    Gökbuget N; Naumann R;
    Onkologie; 2013; 36 Suppl 2():29-35. PubMed ID: 23549034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local institutional review board (IRB) review of a multicenter trial: local costs without local context.
    Ravina B; Deuel L; Siderowf A; Dorsey ER
    Ann Neurol; 2010 Feb; 67(2):258-60. PubMed ID: 20225291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing communication among data monitoring committees and institutional review boards.
    Taylor HA; Chaisson L; Sugarman J
    Clin Trials; 2008; 5(3):277-82. PubMed ID: 18559418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward protecting the safety of participants in clinical trials.
    Califf RM; Morse MA; Wittes J; Goodman SN; Nelson DK; DeMets DL; Iafrate RP; Sugarman J
    Control Clin Trials; 2003 Jun; 24(3):256-71. PubMed ID: 12757992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board.
    Saginur R; Dent SF; Schwartz L; Heslegrave R; Stacey S; Manzo J
    J Clin Oncol; 2008 Mar; 26(9):1479-82. PubMed ID: 18349399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IRBs and monitoring the safety of clinical trials.
    Maloney DM
    Hum Res Rep; 2003 Jan; 18(1):3. PubMed ID: 12755095
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature.
    Check DK; Weinfurt KP; Dombeck CB; Kramer JM; Flynn KE
    Clin Trials; 2013 Aug; 10(4):560-7. PubMed ID: 23666951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An opinion and practice survey on the structure and management of data and safety monitoring boards.
    Tereskerz PM; Guterbock TM; Kermer DA; Moreno JD
    Account Res; 2011 Jan; 18(1):1-30. PubMed ID: 21287412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central IRBs: why are some institutions reluctant to sign on?
    McNeil C
    J Natl Cancer Inst; 2005 Jul; 97(13):953-5. PubMed ID: 15998943
    [No Abstract]   [Full Text] [Related]  

  • 14. Breaking the camel's back: multicenter clinical trials and local institutional review boards.
    Burman WJ; Reves RR; Cohn DL; Schooley RT
    Ann Intern Med; 2001 Jan; 134(2):152-7. PubMed ID: 11177319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The paradoxical problem with multiple-IRB review.
    Menikoff J
    N Engl J Med; 2010 Oct; 363(17):1591-3. PubMed ID: 20942660
    [No Abstract]   [Full Text] [Related]  

  • 17. Ohio CTSAs implement a reliant IRB model for investigator-initiated multicenter clinical trials.
    Cola PA; Reider C; Strasser JE
    Clin Transl Sci; 2013 Jun; 6(3):176-8. PubMed ID: 23751020
    [No Abstract]   [Full Text] [Related]  

  • 18. The IRB is not a data and safety monitoring board.
    Bankert E; Amdur R
    IRB; 2000; 22(6):9-11. PubMed ID: 11883486
    [No Abstract]   [Full Text] [Related]  

  • 19. Problematic variation in local institutional review of a multicenter genetic epidemiology study.
    McWilliams R; Hoover-Fong J; Hamosh A; Beck S; Beaty T; Cutting G
    JAMA; 2003 Jul; 290(3):360-6. PubMed ID: 12865377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical issues during the conduct of clinical trials.
    Silverman H
    Proc Am Thorac Soc; 2007 May; 4(2):180-4; discussion 184. PubMed ID: 17494728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.